LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR?

Similar documents
Chronic Primary Mitral Regurgitation

SUPPLEMENTAL MATERIAL

C. Lutman, L. Vitali Serdoz, G. Barbati, E. Cadamuro, S. Magnani, M. Zecchin, M. Merlo, G. Sinagra

Supplementary Online Content

Restrictive Cardiomyopathy

Congestive Heart Failure or Heart Failure

Diagnosis is it really Heart Failure?

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy

SONOGRAPHER & NURSE LED VALVE CLINICS

CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Prognostic Value of Left Atrial Size and Function

Exercise Pulmonary Hypertension predicts the Occurrence of Symptoms in Asymptomatic Degenerative Mitral Regurgitation

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Athlete s Heart vs. Cardiomyopathy

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on)

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

It has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit

좌심실수축기능평가 Cardiac Function

Diastology State of The Art Assessment

Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin

Abstract ESC Pisa

HFpEF. April 26, 2018

Hypertensive heart disease and failure

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Highlights from EuroEcho 2009 Echo in cardiomyopathies

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Prognostic Impact of FMR

LA Function analysis Marcia Barbosa Vice Presidente - Brazilian Soc of Cardiology President-elect - Interamerican Soc of Cardiology

Valvular Guidelines: The Past, the Present, the Future

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Echo assessment of the failing heart

Cardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement

Cardiac Resynchronization Therapy for Heart Failure

Evaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension

Strain Imaging: Myocardial Mechanics Simplified and Applied

Innovation therapy in Heart Failure

Assessing the Impact on the Right Ventricle

Myocardial Strain Imaging in Cardiac Diseases and Cardiomyopathies.

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Coronary Artery Bypass Graft: Monitoring Patients and Detecting Complications

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Bi-Ventricular pacing after the most recent studies

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Catheter-based mitral valve repair MitraClip System

How atrial fibrillation should be treated in the heart failure patient?

The Management of Heart Failure after Biventricular Pacing

What is the Definition of Small Systemic Ventricle. Hong Ryang Kil, MD Department of Pediatrics, College of Medicine, Chungnam National University

Objectives. Diastology: What the Radiologist Needs to Know. LV Diastolic Function: Introduction. LV Diastolic Function: Introduction

Heart Failure. GP Update Refresher 18 th January 2018

ABLATION OF CHRONIC AF

Heart Failure A Disease for the Internist?

Heart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing

Upgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016

DECLARATION OF CONFLICT OF INTEREST

Cardiac Resynchronization ICD Therapy: What is New?

10/7/2013. Systolic Function How to Measure, How Accurate is Echo, Role of Contrast. Thanks to our Course Director: Neil J.

Echocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Diastolic Heart Function: Applying the New Guidelines Case Studies

Ischemic Mitral Regurgitation

Disclosure Information : No conflict of interest

Athlete s Heart vs. Cardiomyopathy

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation

Atrial dysfunction and chronotropic incompetence

Ventricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC

Transcatheter Echo Guided Mitral Valve Repair with NeoChord Implantation: Results from NeoChord Independent International Registry

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Mechanisms of False Positive Exercise Electrocardiography: Is False Positive Test Truly False?

HFpEF, Mito or Realidad?

Advanced imaging of the left atrium - strain, CT, 3D, MRI -

Evaluation of Left Ventricular Function and Hypertrophy Gerard P. Aurigemma MD

Echocardiographic Correlates of Pulmonary Artery Systolic Pressure

DON T FORGET TO OPTIMISE DEVICE PROGRAMMING

From left bundle branch block to cardiac failure

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Cardiac hypertrophy : differentiating disease from athlete

Copeptin in heart failure: Associations with clinical characteristics and prognosis

Global left ventricular circumferential strain is a marker for both systolic and diastolic myocardial function

HEART FAILURE. Study day November 2018 Sarah Briggs

Transcription:

LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR? Juan Cinca Department and Chair of Cardiology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona, Spain

DISCLOSURE OF INTEREST No conflicts of interest to be declared

/ PROGNOSTIC INDICATOR? Pathophysiological relationship between & HF I) Primary cause of HF Heart Failure II) Secondary condition aggravating HF Heart Failure

OBJECTIVES Primary pathophysiological potential of Experimental models (healthy hearts) Secondary condition aggravating HF Clinical studies Outcomes in HF cohorts

IN HEALTHY HEARTS LV Circumferential Shortening RV * * * * * LV * * * MRI- Dogs (n=8) Ablation of the LBB ACUTE EFFECTS (%) 0 20 0 20 BASELINE SEPTUM Ejection 0 450ms LATERAL Ejection (RF ablation) SEPTUM Ejection LATERAL Ejection CRHONIC EFFECTS Echocardiographic parameters Baseline 16 Weeks LV Ejection Fraction (%) 43±4 33±6* LV Wall Mass (g) 126±31 145±30* LVED Volume (ml) 104±31 135±53* * p<0.05 LV asynchrony (reduction of cardiac output) LV Remodelling (dysfunction, hypertrophy, and dilation) Vernooy K et al Eur Heart J 2005;26:91-98

IN HEALTHY HEARTS Asynchrony & Intra Myocardial Pressure BASELINE (RV pacing) Dogs (n=17) IMP Tissue Pressure Cathter LAD Flow (Doppler) Shortening of diastolic filling ( stroke volume) Increased septal pressure in diastole (compression of septal vessels) Ono S et al, Circulation 1992;85:1125-1131

SECONDARY EFFECTS IN DISEASED HEARTS Diastolic filling and mitral regurgitation DCM DCM with Doppler MVR duration Doppler MVR duration LV filling LV filling A2 A2 S1 S2 S1 S1 S2 S1 DCM n=40 DCM + n= 12 LV Filling (ms) 325±90 190±45* Mitral Regurgitation (ms) 390±60 495±90* *P<0.01 Xiao HB et al, BrHeartJ 1991;66:443-7

SECONDARY EFFECTS IN DISEASED HEARTS LV Asynchrony Normal subject HF+ Li CH, Pons-Llado et al; Int J Cardiovasc Imaging 2010 LV endocardial displacement Speckle trackying 3D-echo Dispersion of time peaks Healthy n=27) Idiopathic (n=35) EF>50% EF<35% Systolic 4±2 12±2 15±3* Diastolic 1±0.6 2±0.6 5±2* Kang SJ et al; Am J Cardiol 2004;93:1243-1246; *P<0.05 induces systolic and diastolic asynchrony

PATHOPHYSIOLOGICAL POTENTIAL OF is a primary cause of LV remodelling and aggravates LV dysfunction in patiens with heart failure

OBJECTIVES Primary pathophysiological potential of Experimental models (healthy hearts) Secondary condition aggravating HF Clinical studies Outcomes in HF cohorts

1-Year Mortality (%) Italian Network on Congestive Heart Failure 150 cardiology centers, FU:1 year (2000); EP:cardiac death Inclusion: CHF NYHA I-IV; N= 5,517 OUTCOMES OF Clinical profile All-cause Death Sudden Death (n=4,126) Age >70 years (%) 30 31 (n=1,391) Male (%) 88.5 70.7* Dilated CM (%) 31.6 49.3* NYHA III-IV (%) 26.4 32.8* LV EF <30% (%) 30.4 49.2* No * p<0.001 HR: 1.36 (1.14-1.61) P:0.0004 HR: 1.34 (1.05-1.72) P<0.01 is an unfavorable prognostic marker in patients with CHF, independent of age, HF severity, and drug prescriptions Baldasseroni S et al, Am Heart J 2002;143:398-405

OUTCOMES OF Enhanced Feedback For Effective Cardiac Treatment (EFFECT) Ontario hospital records; cardiology nurse abstractors; last March 2006; EP: Mortality (Registered Persons DB); N=9,082 Clinical profile (n=6,951) (n=1,480) Age 75.4±12 76.3±11 Male (%) 47.7 49.8* Previous MI(%) 35.1 41.4* S3 (%) 8.6 12* No echocardiographic data * p<0.001 Survival RBBB Adjusted HR (Age,sex,diabetes,ure,hemoglobin,respiratory Diseae,creatinine,LV fnction) : 1.10 (1.02-1.18), p=0.001 RBBB: 1.10 (0.99-1.21), p=0.08 was independently associated with a higher risk of death and rehospitalization for HF or cardiovascular disease Abdel-Qadir HM et al, Int J Cardiol 2011;146:213-218

Henry Ford Hospital-Intensive Care Unit Data Base Detroit,MI. Period: 1990-1998; EP: Mortality at discharge ICU; FU:Vital status (Death Certificate Registry) 27±28 months OUTCOMES OF Clinical profile Survival (n=2,310) (n=386) Age 63±13 63±14 Male (%) 54 54 Previous MI(%) 32 42* LVEF(%) 40±15 29±15* Renal insufficiency (%) 33 40 Severe MV Regurgitation(%) 6.5 9.3 RBBB * p<0.001 HR (adjusted for age,sex, LVEF,renal dysfunction, prior MI.) RBBB+: 1.17 (1,03-1.31), p=0.01 Left and Right BBB are independently associated with higher all-cause mortality after discharge for severe HF McCullough PA et al, Int J Cardiol 2005;102:303-308

OUTCOMES OF Spanish Network for Heart Failure Research (REDINSCOR) 14 hospitals; Consecutive recruitment at HF Units (prior hospitalization );NYHA II-IV; January 2007-January 2010; FU:21 months (11-33); EP: mortality/readmissions. N=2,254 Pathophysiological Categories LV Necrosis LV Dilation LV Hypertrophy LV LV LV Necrotic Q waves Indexed LVED >32mm/m 2 and LVEF<35% N=567 N=672 N=455 LVH with eccentricity Index >0.38

REDINSCOR REGISTRY Clinical Profile of Pathophysiological Categories 80% 70% Male Necrosis (n=567) Dilation (n=672 Hypertrophy (n=455) RR Interval 800 ms 70% Necrosis (n=567) Dilation (n=672 Hypertrophy (n=455) 60% 50% Body Mass Index 28 Kg/m 2 50% 40% 30% Age 67 yr Atrial Fibrillation /Flutter 30% 10% QRS Complex 118 ms Diabetes Mellitus Arterial Hypertension Left Bundle Branch Block is more frequent in LV dilation category

REDINSCOR REGISTRY Outcomes of the Pathophysiological Categories The LV dilation category had the most unfavorable outcome

REDINSCOR REGISTRY Characteristics of patiens with BBB (n=942 )(59%) Left BBB (n=532) (33%) Right BBB (n=134) (8%) Age (yr) 64.7±13.7 66.8±11.6 67.6±12.6* Male (%) 65 71 75* LVNecrosis (%) 32 16 31** LVDilation (%) 19 49 14** LVHypertrophy(%) 24 13 22** LVEDDiameter (mm) 58±10 65±10 57±10** LVEF (%) 39±16 29±10 39±15** LVMass (g) 348±121 404±123 351±103** MVRegurgitation III-IV (%) 15 27 13** Signs of Right HF (%) 39 42 52** * p<0.005 **p<0.0001 Patients with showed the most evolved LV remodelling pattern Patients with RBBB depict more advanced right HF

REDINSCOR REGISTRY Mortality in BBB All cause mortality Cardiovascular death RBBB p<0.0001 RBBB p<0.0001 HR * : 1.41 (1.10-1.81), p=0.006 RBBB: 1.80 (1.23-2.61),p=0.002 HR * : 1.46 (1.10-1.94), p=0.008 RBBB: 1.81 (1.17-2.80),p=0.007 Adjusted for age, diabetes,arterial hypertension, indexed LV mass, left atrial diameter, hemoglobin, estimated glomerular filtration rate.

REDINSCOR REGISTRY Mortality in BBB Cardiac death Pump failure death RBBB p<0.0001 RBBB p<0.0001 HR : 1.62 (1.20-2.19), p=0.001 RBBB: 1.83 (1.15-2.91),p=0.01 HR : 1.59 (1.12-2.26), p=0.009 RBBB: 2.64 (1.61-4.34),p=0.000 Adjusted for age, diabetes, arterial hypertension, indexed LV mass, left atrial diameter, hemoglobin, glomerular filtration rate., RR interval, mitral valve regurgitation, angiotensin converting enzyme inhibitor treatment

PROGNOSIS OF Heart Failure Survey in Israel (HFSIS) March-April 2003; FU: 4 years (all-cause mortality) (n=1389) RBBB (n=193) (n=306) Age (yr) 71 (62-79) 74 (67-81) 76 (68-81) ** Previous MI (%) 62 67 55* NYHA III-IV (%) 35 45 51** LV EF <30% (%) 29 40 51 ** *p<0.05 * *p<0.001 LVEF <50% LVEF <30% RBBB RBBB RBBB vs : HR 1.29 (1.02-1.64) P=0.035 RBBB vs : HR 1.58 (1.09-2.28) P=0.015 All-cause mortality (no causes of death) RBBB but not is associated with increased long-term mortality in patients with HF, especially in those with advanced LV dysfunction Barsheshet A et al; Am J Cardiol 2011:107:540-544)

CONCLUSIONS Prognostic marker? = YES Left BBB is a primary cause of LV remodelling in healthy hearts (via: septal workload-- dilation-- asymmetrical hypertrophy) The concurrence of Left BBB in patients and HF worsens LV function (via: LV filling-- mitral regurgitation-- LV dilation-- LV asinchrony) Left BBB is a prognostic marker of total and cardiac mortality in patients with HF and is more frequently associated with LV dilation Right BBB emerges as a predictor of unfavorable outcome especially in patients with advanced congestive HF (pump failure death)

PROGNOSIS OF Korean Heart Failure Registry 24 hospitals; Acute HF registry; June 2004-April 2009; EP: Mortality and readmissisons Clinical profile (n=1977) (n=107) RBBB (n=118 Age 67±15 71±12 68±15** Male (%) 50 41 58* NYHA III-IV (%) 69 75 80* LVEF(%) 40±15 29±12 39±13.6** Renal failure (%) 9 3.7 9.3 Rehospitalization and death RBBB PAP in LVEF<40%vs >40%: 52±17.5 vs 40±12.4 mmhg, p=0.01 * p<0.05; ** p<0.001 HR adjusted for age,sex,lvef,creatinine,prior MI, diabetes,.) RBBB vs nobbb: 1.91 (1.37-2.6) p<0.001 RBBB vs : 2.57(1.46-4.5) p=0.001 vs nobbb: 0.75 (0.46-1.2) p=0.2 Right BBB is independently associated with worse outomes in patients with acute HF Hong SJ et al, Int J Cardiol 2012; 157(3):416-8